Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Operating Expenses (2023 - 2025)

Historic Other Operating Expenses for Iovance Biotherapeutics (IOVA) over the last 6 years, with Q3 2025 value amounting to $47.5 million.

  • Iovance Biotherapeutics' Other Operating Expenses rose 1511.55% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $194.0 million, marking a year-over-year increase of 13025.65%. This contributed to the annual value of $124.0 million for FY2024, which is 105290.56% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Other Operating Expenses stood at $47.5 million, which was up 1511.55% from $56.7 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Other Operating Expenses ranged from a high of $56.7 million in Q2 2025 and a low of $2.0 million during Q2 2023
  • In the last 3 years, Iovance Biotherapeutics' Other Operating Expenses had a median value of $35.7 million in 2024 and averaged $28.5 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 143014.63% in 2024, then soared by 1511.55% in 2025.
  • Iovance Biotherapeutics' Other Operating Expenses (Quarter) stood at $4.4 million in 2023, then surged by 818.35% to $40.1 million in 2024, then grew by 18.46% to $47.5 million in 2025.
  • Its last three reported values are $47.5 million in Q3 2025, $56.7 million for Q2 2025, and $49.7 million during Q1 2025.